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Abstract
Loss of heterozygosity (LOH) at chromosomal band 9p21 is one of the few consistent
genetic aberrations found in conventional chondrosarcoma. This locus harbours two cell-
cycle regulators, CDKN2A/p16/INK4A and INK4A-p14ARF, which are inactivated in various
human malignancies. It was therefore hypothesized that this locus also plays a role in the
development of chondrosarcoma and this locus was investigated at protein, genetic, and
epigenetic levels. Loss of p16 protein expression was detected by immunohistochemistry
in 12 of 73 central chondrosarcomas and it correlated with increasing histological grade
(p = 0.001). Loss of p16 protein expression was not found in 51 enchondromas, which are
presumed to be potential precursors of conventional central chondrosarcoma. LOH at 9p21
was found in 15 of 39 chondrosarcomas (38%) but it did not correlate with loss of p16
protein expression. SSCP analysis of p16 did not reveal any mutations in 47 cases. Also,
p14 was not the target of LOH, since it gave no aberrant bands on SSCP. To investigate
whether an epigenetic mechanism was operating, methylation-specific PCR was used to look
at p16 promotor methylation, which was identified in 5 of 30 tumours. However, this did
not correlate with protein expression, or with LOH at 9p21. Cytogenetic data were available
in a subset of cases. All tumours that showed chromosome 9 alterations also showed LOH
and loss of INK4A/p16 protein expression. It is concluded that although some alterations
were found at the DNA level and at the promoter expression level, the lack of correlation
between LOH, promotor methylation, and protein expression indicates that a locus other
than CDKN2A/p16 must be the target of LOH at 9p21. The correlation between INK4A/p16
protein expression and tumour grade, and the retention of expression in enchondromas,
indicates that loss of INK4A/p16 protein expression may be an important event during
tumour progression from enchondroma to conventional central chondrosarcoma, and in the
progression in grade after recurrence of chondrosarcoma.
Copyright  2004 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Chondrosarcomas are malignant cartilage-forming
bone tumours, with an occurrence of about 1 in
100 000 in the general population [1,2]. There are three
grades of malignancy that correlate with prognosis [3].
Based on their location in the bone, there are two
major subtypes of conventional chondrosarcomas. The
majority of the tumours are localized in the medullary
cavity of long bones, so-called conventional central
chondrosarcomas. Enchondroma may be its benign
precursor in rare cases. Malignant transformation of
enchondroma is, however, a rare event, especially in
enchondroma of the phalanx, a site where chondrosar-
comas are extremely rare, despite the fact that hands
and feet harbour 35% of enchondromas [4]. A hered-
itary form of conventional central chondrosarcomas
is not known. Enchondromas arising in the context
of Ollier’s disease and Maffucci syndrome, two non-
hereditary conditions displaying multiple enchondro-
mas, carry a much higher risk of malignant transfor-
mation, ie 30–35% (OMIM #166 000) [5]. A minority
of chondrosarcomas arise secondary to a pre-existing
osteochondroma and are termed secondary periph-
eral chondrosarcomas [1,2,6]. We have shown that
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secondary peripheral chondrosarcomas are character-
ized by gross chromosomal instability reflected by
a high percentage of LOH with almost all chromo-
somes involved, and a broad ploidy range [7–9].
In contrast, genetic aberrations in conventional cen-
tral chondrosarcomas are sparse and the tumours are
often (peri)diploid. This suggests that only limited
genetic alterations are sufficient for tumourigenesis
in conventional central chondrosarcomas. Previously,
we demonstrated LOH at 9p21 in 3 of 12 (25%)
conventional central chondrosarcomas. Moreover, a
cytogenetic study of 7 out of 16 conventional central
chondrosarcomas showed cytogenetic aberrations, of
which five involved chromosome 9p12–22 [7]. These
data suggest that the 9p21 region may be important
in its tumourigenesis. At chromosome 9p, an impor-
tant region is the INK4A/ARF locus (9p21), encod-
ing the proteins INK4A/p16 and INK4A/p14ARF. The
activation of INK4A/p16 and INK4A/p14ARF results
in blockage of cell-cycle progression and inhibition
of cellular proliferation. Mutational or transcriptional
inactivation of the CDKN2A/p16 and p14 genes can
lead to uncontrolled growth. CDKN2A/p16 is inacti-
vated in several tumour types, including bone sarco-
mas [10–13], either by homozygous deletion, mutation
or extensive de novo methylation-inhibiting gene tran-
scription [14]. To investigate whether this locus is the
target of the LOH at chromosome 9p in conventional
central chondrosarcomas, we present the results of
immunohistochemistry, LOH analysis, SSCP analysis
(INK4A/p16 and INK4A/ARF), and promoter methy-




All tissue samples were handled in a coded fashion.
The specimen codes indicating patient data were only
available via physicians involved in the diagnosis and
treatment of these patients. All procedures were per-
formed according to local ethical guidelines. Table 1
shows the clinicopathological data of the patients
in this study. In total, 73 tumour specimens from
patients treated between 1986 and 2001 with a histo-
logical diagnosis of conventional central chondrosar-
coma were retrieved from our files. Peripheral, dedif-
ferentiated, mesenchymal, juxtacortical, and clear-cell
chondrosarcomas were excluded. Conventional central
and secondary peripheral chondrosarcomas were dis-
tinguished on the basis of accepted clinicopathological
and radiological criteria [1]. Histological grading was
performed according to Evans et al [3].
In addition, tumour material from 51 enchondromas
was included: 14 enchondromas of the phalanx and
37 enchondromas from other locations in the long
bones. According to the 2002 WHO definition, all
enchondromas were located centrally in the bone, as







Male vs female 28 vs 23 40 vs 33
Median age at diagnosis,
years (range)
36.1 (7–74) 50.8 (18–85)
Histology grade I na 28
grade II na 33
grade III na 12
Ollier’s disease 4 of 51 4 of 73
Phalanx vs not phalanx 14 vs 37 0 vs 73
Median follow-up, months
(range)
75 (2–178) 56.5 (1–187)
Mean disease-free survival,
months (range)
68.8 (2–178) 49.8 (1–169)
documented by X-ray. Phalangeal and non-phalangeal
localizations were analysed separately. An expert
bone-tumour pathologist reviewed all cases to confirm
the diagnosis. Formalin-fixed, paraffin wax-embedded
tissue was available from all patients; for a subset
of chondrosarcomas (n = 47), fresh frozen tissue was
also available. Follow-up data were retrieved from
clinical charts and from the files of The Netherlands
Committee on Bone Tumours.
Immunohistochemistry
Immunohistochemical staining was performed with
the monoclonal INK4A/MTS1 antibody (Neomarkers,
Fremont, CA, USA) according to standard laboratory
methods [15]. In short, antigen retrieval was per-
formed using 0.01 M citrate solution. Sections of tonsil
were used as a positive control. The staining inten-
sity (0 = negative, 1 = weak, 2 = moderate, and 3 =
strong intensity) and the percentage of positive cells
(0 = 0%, 1 = 1–24%, 2 = 25–49%, 3 = 50–74%,
and 4 = 75–100%) were evaluated by two observers
independently [8]. In discrepant cases, the sections
were re-analysed to obtain a consensus. Haematopoi-
etic cells in bone marrow or endothelial cells served
as an internal positive control to evaluate whether
negative tumour cells were truly negative or whether
prolonged decalcification might have altered the con-
formation of the antigen, resulting in a false-negative
result. INK4A/p16-negative tumours without a posi-
tive internal control were excluded.
Loss of heterozygosity and CDKN2A/p16 and
p14ARF SSCP analysis
DNA isolation
Paraffin wax-embedded cartilaginous tissue is not suit-
able for DNA analysis because the decalcification
process with formic acid results in DNA degrada-
tion. From 40 patients with chondrosarcomas, DNA
from fresh-frozen tissue and matched normal DNA
were available. Only tumour tissue was available
from seven patients. Normal DNA was prepared from
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peripheral blood drawn from patients after informed
consent, or from normal muscle or skin obtained from
resected specimens. Tumours with tumour cell per-
centages over 60% were included for genetic analysis
[8]. No frozen material was available from enchon-
dromas. DNA isolation from frozen sections was per-
formed using proteinase K treatment and subsequent
purification with the Wizard Genomic DNA Purifica-
tion Kit (Promega, Madison, WI, USA) according to
the manufacturer’s instructions. DNA from blood sam-
ples was isolated using a salting-out procedure [16].
LOH analysis
No matching normal DNA was available from
seven samples and therefore those seven samples
were not suitable for LOH analysis, leaving 40
tumours. For the study of LOH on chromosome
9p, the following polymorphic microsatellite markers
were used: D9S269, D9S274, D9S319, and D9S304
(http://gdbwww.gdb.org).
The location of the markers in relation to
CDKN2A/p16/INK4A is shown in Figure 1.
LOH analysis and scoring have been described
previously [17]. LOH results had to be reproducible
in a consecutive analysis.
CDKN2A SSCP analysis
Genomic DNA from 47 tumours was used for
SSCP analysis. Both genes encoded by the CDKN2A
locus, p16 and p14/ARF, were investigated. The
CDKN2A/p16 gene was screened as described pre-
viously and covers the entire open reading frame [18].
Additional primers were designed for the p14/ARF
exon 1β. Exon 1β was divided into two overlap-
ping fragments. Primers for the two fragments of
exon 1β were F1: 5′-CACCTCTGGTGCCAAAGG-
3′ and R1: 5′-GCCTCCTCAGTAGCATCAGC-3′ (A
fragment 219 bp), and F2: 5′-GCCGCGAGTGAGGG-
TTTT-3′ and R2: 5′-CACCGCGGTTATCTCCTC-3′
(B fragment 257 bp).
Methylation-specific PCR (MSP) analysis
Promoter methylation was determined according to
Herman et al [19], based on bisulphite modification
and subsequent PCR specific for the methylated versus
the unmethylated CDKN2A/p16 promoter sequence.
One microgram of genomic DNA from 30 fresh-
frozen tumours was used for MSP analysis and
modified using the CpGenome DNA Modifica-
tion Kit (Intergen, New York, USA). Subsequent
CDKN2A/p16-promoter methylation status was anal-
ysed using the CpG WIZ Amplification Kit (Intergen,
New York, USA). After amplification, samples, methy-
lated, unmethylated, and wild-type controls were anal-
ysed on a 2% agarose gel.
Statistical analysis
The SPSS package was used for all statistical analy-
ses. Histological parameters were analysed using the
chi-square test for trend. Kaplan–Meier curves and
the log-rank test were used to study the effect of




In total, 14 of 69 (20%) chondrosarcomas demon-
strated complete loss of INK4A/p16 protein expres-
sion (Figure 2C), which was restricted to higher-grade
lesions: 0 (0%) of 24 grade I chondrosarcomas demon-
strated loss of expression, compared with 9 (27%)
of 33 grade II and 5 (42%) of 12 grade III chon-
drosarcomas (p = 0.001, chi-square test for trend). In
contrast, none of the enchondromas showed loss of
INK4A/p16 expression. One of eight patients with
Ollier’s disease demonstrated loss of INK4A/p16 pro-
tein expression in a grade II conventional central chon-
drosarcoma. The results of the immunohistochemical
analysis of INK4A/p16 staining are shown in Table 2.
Immunohistochemical INK4A/p16 staining can result
in positive nuclear or cytoplasmic staining. In the
tumours tested, we found both nuclear and cytoplas-
mic staining (Figure 2A). Five of 73 samples showed
only cytoplasmic staining. There were also some cases
showing focal positive INK4A/p16 staining as shown





















Figure 1. Schematic representation of the CDKN2A/p16 and p14ARF genes, flanked by the markers on chromosome 9p21 that
were used for LOH analysis
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Figure 2. Light micrograph showing the immunohistochemical nuclear and cytoplasmic localization of INK4A/p16. (A) Positive
staining for INK4A/p16 in a grade II conventional central chondrosarcoma. (B) Some conventional central chondrosarcomas
showed focal positive INK4A/p16 staining (arrows). (C) Fifteen per cent of conventional central chondrosarcomas were entirely
negative for INK4A/p16; the inset shows the internal positive control (endothelial cells)
Table 2. Results of p16 immunohistochemistry stratified





Total enchondroma 0/39 (0%)
Conventional central chondrosarcomas
Grade I 0/24 (0%)
Grade II 9/33 (27%)∗
Grade III 5/12 (42%)
Total conventional central chondrosarcomas 14/69 (20%)
∗ One INK4A/p16-negative grade II tumour originated from an
Ollier’s disease patient.
in Figure 2B. Four specimens could not be evalu-
ated due to repeated loss of tissue attachment during
microwave procedures.
LOH and CDKN2A SSCP analysis
SSCP
To investigate if CDKN2A/p16 and p14/ARF are
inactivated by a genetic mutation, we carried out
SSCP analysis on the four exons encoding these
genes and performed LOH analysis with polymor-
phic microsatellite markers adjacent to the CDKN2A
locus. SSCP was chosen as the technique to deter-
mine mutations because the method has proven useful
for the identification of INK4A mutations previously
in melanoma [18] and because it is able to detect
up to 90% of mutations in a background of non-
tumour tissue, which is not possible by sequencing.
In two samples from melanoma patients with previ-
ously confirmed CDKN2A/p16 mutation in exon 2
from CDKN2A/p16, an aberrant SSCP pattern could
be detected, validating the SSCP analysis. None of
the 47 chondrosarcomas revealed aberrant bands at
the CDKN2A/p16 and p14/ARF loci. Figure 3 shows
an example of SSCP analysis on five chondrosar-
comas and a melanoma with a known mutation
in p16.
LOH
As shown in Table 3, LOH at 9p21 for one or more
markers was found in 15 of 40 (37.5%) cases. LOH
was mainly found in grade II and III tumours. LOH
for one or more markers in the 9p21 region was found
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Figure 3. Example of SSCP analysis of p16 exon 2, c
fragment. Lanes 1–5 represent PCR products from five different
conventional central chondrosarcoma samples and + is a
melanoma sample containing a known mutation in exon 2.
An arrow indicates the band shift in the positive control
in 2 of 10 (22%) grade I, 11 of 21 (52%) grade II, and
4 of 6 (67%) grade III chondrosarcomas (p = 0.054,
chi square test for trend).
For 12 cases, all informative markers at 9p showed
LOH. There was also one tumour that showed loss of
one marker and retention of an adjacent one, but the
region involving LOH included the INK4A locus in
all cases.
Remarkably, for all three patients with Ollier’s
disease, LOH for one or more markers in the 9p21
region was found.
As shown in Table 3, there was no clear correlation
between LOH at 9p and the loss of protein expression.
Promoter methylation
Table 4 shows the results of promoter methylation
analysis by MSP. An example of MSP is shown
in Figure 4. DNA was available to study promoter
methylation from six of ten patients with absent
INK4A/p16 protein expression. Twenty-four addi-
tional patients were selected with varying INK4A/p16
staining intensities with INK4A/MTS1 antibody.
Methylation of the CDKN2A/p16 promoter was
detected in 5 of 30 (13%) cases. Detectable promoter
methylation was not clearly associated with loss of
INK4A/p16 protein expression (Table 4).
Statistical analysis
There was a significant relationship between loss of
INK4A/p16 protein expression and increasing tumour
grade (chi-square test for trend, p = 0.004). Both
LOH for one or more markers in the 9p21 region
and complete loss of INK4A/p16 expression also
seemed to correlate with poor prognosis; this was,
however, not statistically significant (p = 0.0828 and
p = 0.1271, respectively, log-rank test) and was not
independent of histological grade, which was a strong
prognostic parameter (p = 0.000, log-rank test).
Table 3. Correlation between loss of p16 protein expression and LOH at 9p21









Grade I 2 0/2 9 0/6∗ 11
Grade II 9 1/7 (14%)∗ 14 1/11 (9%)∗ 23
Grade III 4 2/4 (50%) 2 1/2 (50%) 6
Total 15 3/13 (23%) 25 2/25 (8%) 40
∗ No corresponding p16 protein expression data were available from eight tumours with LOH data.
Table 4. Correlation between CDKN2A/p16 methylation status, tumour grade, and INK4A/p16
immunohistochemistry
Conventional central chondrosarcoma p16 Methylation
Grade I 0/7 (0%)
Grade II 4/17 (24%)
Grade III 1/6 (17%)
Conventional central chondrosarcoma p16 intensity p16 % positive cells
p16 expression 0 1/6 (17%) 0 0
p16 expression 2 2/6 (33%) 1 1
p16 expression 3–4 1/10 (10%) 1 2
p16 expression 5–6 1/5 (20%) 2 3
p16 expression 7 0/3 (0%)
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Figure 4. Example of MSP analysis. All DNAs were modified
with bisulphite. The samples in lanes 1–4 were amplified with
primers for the methylated state and those in lanes 5–8 were
amplified with primers for the unmethylated state. Lanes 1 and
5 are of a conventional central chondrosarcoma; lanes 2 and 6
are unmethylated control DNAs; lanes 3 and 7 are methylated
control DNAs; and lanes 4 and 8 are samples amplified without
DNA to serve as a negative control. Lane M is a 100 bp ladder
Ten of 27 chondrosarcomas that showed INK4A/p16
expression also showed LOH. The staining intensity
and the percentage of cells demonstrating INK4A/p16
expression seemed slightly lower in INK4A/p16-
positive tumours with LOH than in INK4A/p16-
positive tumours without LOH, although the difference
was not statistically significant (mean score for inten-
sity 1.38 versus 1.74, mean score for percentage of
positive cells 1.54 versus 2.05, mean total score 2.92
versus 3.79).
Discussion
Few genetic aberrations have been identified in con-
ventional central chondrosarcomas, suggesting that
limited genetic alterations are required for tumourige-
nesis. LOH and other cytogenetic alterations at 9p21
are, however, repeatedly found, suggesting an impor-
tant role in tumourigenesis for genes located in this
region. The CDKN2A/p16 locus at 9p21 is an excel-
lent candidate, since it has been shown to be inacti-
vated in multiple tumour types including bone sarco-
mas [14]. The CDKN2A/p16 gene has been investi-
gated previously in chondrosarcoma, but a heteroge-
neous group of chondrosarcomas was used and only
one genetic alteration was found [20]. These authors
identified promoter methylation in 5 of 22 cases, but
loss of expression was not confirmed by immunohis-
tochemistry.
Here we present a carefully selected group of
conventional central chondrosarcomas only, stratified
according to differentiation, grade and aetiology, and
their potential precursors, namely enchondromas. A
study for CDKN2A/p16 was performed at the level
of protein, genetic alterations, promoter methylation,
and mutational analysis of p14/ARF. Furthermore, we
investigated whether INK4A/p16 protein expression
level can be used as a predictive marker for tumour
progression in conventional central chondrosarcomas.
Two separate subgroups were discerned within our
tumours:
(1) Tumours located in the phalanx versus those
located elsewhere, since phalangeal chondrosarco-
mas are extremely rare and have a far better prog-
nosis than chondrosarcomas located elsewhere [4].
Both enchondromas of the phalanx and enchon-
dromas located elsewhere failed to demonstrate
loss of INK4A/p16 protein expression.
(2) Conventional central chondrosarcomas that occur
in the context of Ollier’s disease [5,21] versus
sporadic cases. Chondrosarcomas in the context
of Ollier’s disease may have a worse prognosis
than normal chondrosarcomas [22,23]. Four chon-
drosarcomas from patients with Ollier’s disease
were available for this study and one showed loss
of INK4A/p16 protein expression. Remarkably,
however, all three patients with Ollier’s disease
used for the LOH analysis demonstrated LOH for
one or more markers in the 9p21 region. This
is consistent with previous data [24] and sug-
gests that INK4A/p16 is not more often involved
in Ollier’s disease than in non-Ollier’s disease-
related chondrosarcomas. Rather, another gene
located in the 9p21 region may be important in
chondrosarcoma in Ollier’s disease.
This study shows that conventional central chon-
drosarcomas demonstrate loss of INK4A/p16 expres-
sion by immunohistochemistry in 20% of cases tested
and that this loss increases with histological grade.
Enchondromas show no loss of INK4A/p16 expres-
sion. This is concordant with the low proliferative
activity in enchondromas and the role of INK4A/p16
in inhibition of cell-cycle progression. In dysplastic
nevi, LOH, mutations, and loss of protein expression
of INK4A/p16 have been reported but only in a small
fraction, whereas melanomas often show INK4A/p16
alterations, suggesting a role for this gene in tumour
progression in this situation too [25–28]. Five tumours
showed only cytoplasmic and no nuclear staining. It
has previously been described that breast tumours with
only cytoplasmic INK4A/p16 staining behave more
aggressively [29], but this cannot be concluded for
chondrosarcomas because the tumours that showed
only cytoplasmic staining were low grade.
In many other tumours, especially melanoma,
the CDKN2A/p16 locus is the target for LOH
at 9p21 [18,30,31]. Our LOH analysis shows that
CDKN2A/p16 is included in the region in all cases
with LOH of at least one marker at 9p21. LOH at
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9p21 was relatively frequent (37%) and comparable
to previous results [8,32,33].
LOH at 9p increased with histological grade, which
is most probably a reflection of an overall increase
in genetic instability in higher-grade tumours [34].
Whether CDKN2A/p16 is the target of LOH at chro-
mosome 9p21 could not be assessed because SSCP
analysis did not identify mutational inactivation of
the retained copy of CDKN2A/p16 and p14ARF in
any of the tumours tested. Furthermore, there was no
association between LOH at 9p21 and immunohisto-
chemical loss of INK4A/p16 protein expression. The
9p12–22 region was involved in five of seven con-
ventional central chondrosarcomas with an aberrant
karyotype [35]. Two of the five cases demonstrat-
ing −9, t(9;10)(p22;q22) and add(9)(p21) could be
included in the present analysis and both showed loss
of INK4A/p16 protein expression and LOH at 9p21.
Homozygous deletions of the CDKN2A region have
been described occasionally in cell lines and primary
tumours of different origins [14,36,37]. We cannot
exclude the possibility that such deletions have been
missed in our study. However, because there is no
obvious relationship between LOH and INK4A/p16
protein expression in our study, homozygous deletions
of CDKN2A/p16 in conventional central chondrosar-
comas are unlikely.
Another mechanism for tumour suppressor gene
inactivation is epigenetic promoter methylation, which
has been described for the CDKN2A/p16 gene [19,38].
Indeed, we found methylation in 5 of 30 patients.
However, there was no association between LOH at
9p21 and methylation, since only two of these cases
showed LOH. There was no significant relationship
between protein expression and CDKN2A/p16 pro-
moter methylation, since we identified four tumours
that showed promoter methylation without loss of
INK4A/p16 protein expression. With increasing age,
methylation of several target genes can be detected
in normal tissue [39–41]. The average age of the
patients that showed CDKN2A/p16 promoter methy-
lation was 41.4 years. This is even less than the
average age of all patients with conventional central
chondrosarcomas, namely 50.8 years, thereby indicat-
ing that age-dependent promoter methylation is not
likely. An alternative explanation for the discordance
between CDKN2A/p16 promoter methylation and pro-
tein expression is the presence of focal INK4A/p16-
positive areas next to areas with no INK4A/p16
expression (Figure 2B), indicating tumour heterogene-
ity with regard to INK4A/p16 promoter methylation.
Interestingly, we did not find promoter methylation in
low-grade chondrosarcomas.
CDKN2A/p16 alterations have also been identified
in other bone sarcomas, such as osteosarcomas [10,11],
Ewing sarcomas [10,12], and malignant fibrous his-
tiocytomas of bone (MFH-b) [13]. About 30% of
Ewing sarcomas and osteosarcomas show abnormal-
ities (mutations, deletions, and promoter methylation)
of the INK4A locus. For MFH-b, only 1 of 19 tumours
showed a CDKN2A/p16 mutation. Ewing sarcomas
show a negative correlation between mutations and
deletions of the INK4A locus and prognosis.
In conclusion, loss of INK4A/p16 protein expression
occurs in one-third of conventional central chondrosar-
comas by an as yet unknown mechanism and is asso-
ciated with higher tumour grade. Although we found
LOH at 9p21 in 38% of cases, there was no association
between LOH and loss of INK4A/p16 protein expres-
sion. Thus, neither the CDKN2A/p16 nor the p14ARF
locus appears to be the target and therefore another
gene is most likely involved by this recurrent genetic
aberration. Also, CDKN2A/p16 promoter methylation
does not explain this phenomenon, because we did
not find an association with loss of protein expres-
sion. It is of importance that CDKN2A/p16 loss is
more frequent in high-grade tumours and is absent in
enchondroma. It has been reported that recurrences of
chondrosarcoma sometimes demonstrate an increase
in the degree of malignancy [1,2]. This suggests that
loss of INK4A/p16 protein expression is an important
event during tumour progression in enchondroma, as
well as for the progression in grade in recurrent chon-
drosarcoma.
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